On 3 September 2026, HENGRUI PHARMA (01276.HK) announced that the NMPA has approved the domestic registration and marketing of oteseconazole capsules (0.15g, Class 4 chemical drug) developed by its subsidiary Chengdu Shengdi, for the treatment of severe vulvovaginal candidiasis (VVC); the drug is an oral small-molecule fungal CYP51 inhibitor introduced from the US company Mycovia, and this approval covers the transfer of the overseas-produced drug to domestic production.
On 3 September 2026, HENGRUI PHARMA (01276.HK) announced that the NMPA has accepted the marketing application for Zhuotuoqibai injection (SHR-1819), an IL-4Rα-targeting antibody independently developed by its subsidiary Guangdong Hengrui, for moderate to severe atopic dermatitis in adults; the Phase III study (652 patients) met both co-primary efficacy endpoints with results significantly superior to placebo.
On 3 September 2026, HENGRUI PHARMA (01276.HK) announced that the NMPA has accepted the marketing application for HRS-7535 tablets, an oral small-molecule GLP-1 receptor agonist developed by its subsidiary Shandong Shengdi, for long-term weight management in adults (obesity or overweight with comorbidities); the pivotal Phase III study showed an average weight reduction of up to 11.1% in the 180mg group at week 50.
On 4 September 2026, TENCENT MUSIC-SW (01698.HK) announced the pricing of its public offering of USD 1 billion senior unsecured notes in two tranches — USD 500 million at 5.050% due 2031 and USD 500 million at 5.650% due 2036 — with expected net proceeds of approximately USD 991.9 million for offshore debt refinancing and share repurchases; the notes are expected to be listed on HKEX.
On 3 September 2026, CIRC (01763.HK) announced that the coupon rate of its 2026 sci-tech innovation corporate bonds to professional investors (Tranche 1, with an issue size of no more than RMB 500 million and a three-year tenor) has been determined at 1.50% following bookkeeping, with the offline issue scheduled for 4 and 7 September.
On 3 September 2026, SIMCERE PHARMA (02096.HK) announced that Yimule (Kulaiweibai injection), a domestic Class 1 innovative biologic developed in strategic cooperation with Ruiyang, has been approved by the NMPA for marketing in China, for the prevention of RSV-associated lower respiratory tract infection in neonates and infants; Phase III data showed 85.32% protective efficacy against RSV-associated lower respiratory tract infection requiring medical intervention and 83.27% against RSV-associated hospitalisation at 150 days after administration.
On 3 September 2026, GOLDEN FAITH GP (02863.HK) announced that chairman and executive director Mr. Ko Chun Hei has placed his entire shareholding of 119,595,000 shares (approximately 17.34%) through a placing agent, and no longer holds any shares after completion; all placees are independent third parties, and no single placee may hold 30% or more of the issued share capital after the placing.
On 4 September 2026, GANFENGLITHIUM (01772.HK) announced that the reduction plan of vice president Mr. Fu Lihua (up to 40,000 shares, during 4 June to 3 September 2026) has expired without implementation, with his holding unchanged at 215,050 shares (0.010% of the total share capital).
On September 3, 2026, FUTURE BRIGHT (00703.HK) announced that its wholly-owned subsidiary Chun Ying had entered into two renovation contracts with an independent contractor for its Edo Japanese Restaurant, with lump-sum contract prices of MOP 1,130,000 (approximately HKD 1,096,100) and MOP 13,300,000 (approximately HKD 12,901,000), covering civil and waterproofing works and premium decoration and electrical and mechanical installation works respectively, with the latter expected to be completed in the fourth quarter of 2026. Aggregated under the Listing Rules, the two contracts constitute a discloseable transaction exempt from the circular and shareholders' approval requirements.
On September 3, 2026, DL HOLDINGS GP (01709.HK) announced that its Bitcoin mining business had produced an aggregate of 506.228 Bitcoins since commencing on November 12, 2025, with 405.00 Bitcoins sold at an average price of approximately USD 74,021 each for approximately USD 29.98 million in realized value, and 101.228 Bitcoins still held as of September 2, 2026. The average electricity cost per Bitcoin has declined from a cumulative approximately USD 54,500 to approximately USD 50,000 in August 2026, and the group expects to produce approximately 240 to 264 Bitcoins during the remaining period ending December 31, 2026; the figures have not been audited or reviewed by the company's auditors.
On September 3, 2026, SBP GROUP (01177.HK) announced that TQB6426, a national Class 1 innovative drug and a GPC3-targeting antibody-drug conjugate independently developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., had received IND approval from the US FDA for advanced malignant tumors. GPC3 is highly expressed in hepatocellular carcinoma and no GPC3-targeting ADC has been approved worldwide; the group will accelerate the Phase I clinical trial to evaluate the drug's safety, tolerability, pharmacokinetic profile and preliminary efficacy.
On September 3, 2026, TWINTEK (06182.HK) announced that Mars Nest Limited, its controlling shareholder, had sold 510,000,000 shares of the company, representing approximately 63.75% of its total issued share capital; immediately upon completion, Mars Nest no longer held any shares and ceased to be the controlling shareholder. The company cautioned shareholders and potential investors to act with prudence when dealing in its shares.
On September 3, 2026, ASYMCHEM (06821.HK) issued an overseas regulatory announcement stating that 1,027,575 A shares under the first release tranche of the initial grant of its 2025 A-share restricted share incentive plan, representing 0.3087% of its A-share capital and involving 540 grantees, will be released from trading restrictions and listed for trading on September 7, 2026. The first sales restriction period ended on September 4, 2026, and the company's 2025 revenue of RMB 6.670 billion, up 16.78% at constant exchange rates, satisfied the performance assessment requirements.
On September 3, 2026, EDICO HOLDINGS (08450.HK) issued a supplementary announcement stating that financial printing remains its principal business with no intention to downscale it in the next twelve months, with interim revenue up approximately 47.1% to approximately HKD 12.6 million, and that the company holds a 51% interest in and majority control over HKTCG, the vehicle of its trading card business. In response to a Sing Tao news article, the company clarified that cards worth approximately HKD 80 million displayed in its retail stores include collectors' own property for exhibition purposes only, and that the reported outlay of approximately HKD 60 million by Mr. Chung reflects an estimate of potential resources for the card business over the next three to five years rather than an actual investment.
NewTimeSpace News: September 03, 2026, SMARTONE TELE(00315.HK) released its Annual Report for the period ended June 30, 2026, Total Revenue stood at HKD 6.6 billion, increased by 5.6% YoY.
On September 3, 2026, MEDIA CHINESE (00685.HK) announced that its indirect wholly-owned subsidiary Ming Pao Holdings (Canada) Limited had agreed to dispose of a property in Richmond, Canada, formerly used as the group's media office and printing plant, to Da Xing Investment Ltd. for CAD 6.85 million (approximately USD 4.92 million), expecting to record an unaudited gain of approximately CAD 5.26 million, with net proceeds of approximately CAD 6.55 million planned for general working capital. The disposal constitutes a discloseable transaction, with completion expected on December 1, 2026.
